StreetAlpha.app
Home › Stocks › VOR

Vor Biopharma Inc. (VOR)

Healthcare
$18.18
▼ −4.16%
LAST CLOSE · NOV 17

Vor Biopharma is developing telitacicept, an investigational treatment for autoimmune diseases. It last closed at $18.18 on Nov 17, down 4.16% on the day.

AI Auto Pilots
Is VOR in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Net income
$1.4B
Free cash flow
−$119.7M
Valuation
Market cap
$1.1B
61.4M shares
P/E
–
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$79.0M
At Sep 30
Shareholder equity
−$137.2M
Shares outstanding
61.4M
At Oct 26
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: −$68.9M−$68.9MFY2021FY2022: −$92.1M−$92.1MFY2022FY2023: −$117.9M−$117.9MFY2023FY2024: −$116.9M−$116.9MFY2024FY2025: −$696.0M−$696.0MFY2025

From VOR's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Oct 30). Last 12 months adds up the four latest quarters.

Next report
—
No date on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
—
No ratings in 90 days
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Consensus · 90 days
No firm has rated VOR in the past 90 days.
Average 12-month target
No price targets on VOR in the past 90 days.
Latest rating changes
WedbushMaintained
Aug 12Hold$27
DateFirmActionRatingPrice target
Aug 12WedbushMaintainedHold$27
Loading…

Technical Analysis

VOR · as of the Nov 17 close · updated after every close
Pullback inside a longer uptrend

The stock is 7% below its 20 day and 9% below its 50 day average. It is 3% above its 200 day average, so the longer trend is still up. Momentum is weak (RSI 42). The nearest support is the swing low (Oct 7) at $17.86, and the nearest resistance the Pivot at $18.33.

Short trendBearish
Long trendBullish
MomentumWeak
StretchNormal
VolatilityNormal, 6.7%/day
Key levels
$26.0052 week high+43.0%
$20.55100 day average+13.0%
$19.79Swing high (Oct 21)+8.9%
$19.7350 day average+8.5%
$19.4320 day average+6.9%
$18.89Pivot R1+3.9%
$18.33Pivot+0.8%
$18.18Last close
$17.86Swing low (Oct 7)−1.8%
$17.62Pivot S1−3.1%
$17.59200 day average−3.2%
$6.5052 week low−64.2%
Indicators
RSI (14)41.71Middle of its rangeNeutral
MACD-0.16Below its signal lineBearish
Stochastic23.5Middle of its rangeNeutral
ADX (14)9.2No clear trend
Williams %R-89.8Oversold below −80, overbought above −20Oversold
CCI (20)-131.5Oversold below −100, overbought above 100Oversold
Rate of change−8.5%Change over 10 sessionsBearish
ATR (14)$1.22Typical daily range, 6.7% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Above
What happened before, for VOR

What happened before

See how VOR did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow VOR usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How VOR has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2021.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in VOR in the last 90 days.

Loading…

See today’s whale options flow across the market →

VOR Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Strongly bullish
Strongly bearishNeutralStrongly bullish
  • ▲104 buying vs 51 selling
  • ▲Held by funds +9.7 pts
  • ▲Funds holding +54
  • ▲Superinvestors: 3 added, 1 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding156102+52.9%
In funds' top 1065+20.0%
Held by funds90.0%80.3%+9.7 pts
New / increased64 / 4038 / 35+42.5%
Reduced / sold out39 / 1219 / 17+41.7%
Put/call ratio0.00––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See VOR institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether VOR is in one of them and how their past VOR trades turned out.

VOR in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered VOR in an article yet. Here's the latest on the wider market.

About Vor Biopharma

Vor Biopharma is a biopharmaceutical company based in Boston, Massachusetts, that is developing telitacicept, a treatment for autoimmune diseases. Telitacicept is a fusion protein that acts on two signaling molecules involved in B cell activity, and the company is studying it in conditions such as generalized myasthenia gravis and Sjögren's disease. It holds rights to the drug outside Greater China and is running advanced trials aimed at approval in the United States, Europe and Japan. Its intended users are patients with autoimmune diseases and the doctors who treat them.

Headquarters
Boston, MA